Skip to main content

Acute Myeloid Leukaemia

9
Pipeline Programs
8
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
4
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Impact Therapeutics
Impact TherapeuticsChina - Shanghai
1 program
1
VyxeosPhase 2/3
Servier
ServierFrance - Suresnes
2 programs
1
1
S 64315Phase 1/21 trial
S 64315Phase 11 trial
Active Trials
NCT03672695Completed37Est. May 2023
NCT04629443Completed17Est. Aug 2023
Biocorp
BiocorpFrance - Issoire
1 program
1
U32 CAR-TPhase 1/2Cell Therapy1 trial
Active Trials
NCT07036250Recruiting20Est. Dec 2029
Medica Corp
Medica CorpMA - Bedford
1 program
1
WT1 TCR-transduced T cellsPhase 1/2
Catapult Therapeutics
Catapult TherapeuticsNetherlands - Lelystad
1 program
1
WT1 TCR-transduced T cellsPhase 1/21 trial
Active Trials
NCT01621724Completed7Est. May 2018
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
AZD1152Phase 11 trial
AZD1152Phase 11 trial
Active Trials
NCT01019161Completed5Est. Jun 2010
NCT00530699Completed30Est. Aug 2009
Hikma
HikmaNJ - Berkeley Heights
1 program
1
AzacitidinePhase 11 trial
Active Trials
NCT06326697Completed32Est. Aug 2025
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
VyxeosPHASE_2_31 trial
Active Trials
NCT04217278Unknown333Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Jazz PharmaceuticalsVyxeos
BiocorpU32 CAR-T
ServierS 64315
Catapult TherapeuticsWT1 TCR-transduced T cells
HikmaAzacitidine
ServierS 64315
AstraZenecaAZD1152
AstraZenecaAZD1152

Clinical Trials (8)

Total enrollment: 481 patients across 8 trials

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Start: Jan 2020Est. completion: Mar 2025333 patients
Phase 2/3Unknown

Clinical Study of U32 in Patients With Acute Myeloid Leukemia

Start: Jul 2025Est. completion: Dec 202920 patients
Phase 1/2Recruiting

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Start: Feb 2021Est. completion: Aug 202317 patients
Phase 1/2Completed
NCT01621724Catapult TherapeuticsWT1 TCR-transduced T cells

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Start: Apr 2012Est. completion: May 20187 patients
Phase 1/2Completed
NCT06326697HikmaAzacitidine

Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

Start: May 2024Est. completion: Aug 202532 patients
Phase 1Completed

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Start: Nov 2018Est. completion: May 202337 patients
Phase 1Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Start: Nov 2009Est. completion: Jun 20105 patients
Phase 1Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Start: Nov 2007Est. completion: Aug 200930 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 481 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.